This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SYT1 / Synaptotagmin-1 · IHC design guide
Design Immunohistochemistry for SYT1
Plan SYT1 chromogenic IHC on paraffin sections using the high cerebellar GLUC-cell and medium cortical neuropil staining as references (HPA tissue IHC). The guide covers controls, interpretation, and the catalog antibody’s 0.5–1 μg/ml IHC starting range (datasheet A02314-1).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SYT1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | CNS neuropil (HPA tissue IHC); vesicle membrane (UniProt) | |
| Staining pattern | CNS neuropil; cerebellar GLUC cell cytoplasm/membrane (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A02314-1) | |
| Positive control | Cerebellum+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific) | |
| Caveat | Melanocyte expression may add non-neural signal (UniProt) | |
| Regulation | Expression regulation not reported (UniProt) | |
| Isoform / epitope | 0 isoforms; vesicular versus cytoplasmic epitope matters (UniProt) |
Section 1
Recommended SYT1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with a published chromogenic SYT1 protocol in human postmortem brain (PMC7264177).
| Sample | Paraffin-embedded human glioma tissue; fixative not specified (datasheet A02314-1) |
| Fixation | Image fixative and duration unreported (datasheet A02314-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A02314-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02314-1) |
| Primary antibody | Rabbit anti-SYT1, 0.5-1μg/ml (datasheet A02314-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02314-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A02314-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SYT1-positive staining in gLUC cells - cytoplasm/membrane of cerebellum (HPA tissue IHC: High). HPA tissue profile: Selective expression in neuropil in CNS. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 (datasheet: A02314-1); the published chromogenic protocol does not specify retrieval (PMC7264177).
Section 2
What Is the Expected SYT1 Staining Pattern?
SYT1 is a synaptic and secretory vesicle membrane protein with a vesicular N terminus and cytoplasmic C terminus (UniProt P21579 topology). In paraffin section IHC, expect selective CNS neuropil staining, high cytoplasm/membrane staining in cerebellar GLUC cells, and medium neuropil staining in cerebral cortex (HPA tissue IHC). HPA rates the tissue pattern Enhanced, citing consistency between antibody staining and RNA expression (HPA tissue IHC).
| Cerebellar GLUC cells show strong cytoplasm/membrane staining; cortical neuropil stains less strongly. | This matches the reported High cerebellar and Medium cortical patterns (HPA tissue IHC). Assess the stained compartment and cell population together; signal intensity alone cannot establish specificity (general IHC practice). |
| The dominant signal is nuclear or uniformly fills cells instead of following cytoplasm/membrane or neuropil. | That distribution conflicts with the reported tissue pattern and vesicle membrane localization (HPA tissue IHC; UniProt P21579 subcellular location). Check whether background or nonspecific detection explains it before scoring the section as SYT1 positive (general IHC practice). |
| Adipocytes or adrenal glandular cells stain prominently. | HPA reports SYT1 as Not detected in those specified cell populations (HPA tissue IHC). Unexpected staining raises concern for cross-reactivity or endogenous detection activity; it does not by itself identify which is responsible (general IHC practice). |
| Color is diffuse across tissue, including areas outside the expected cell populations. | Widespread haze obscures the selective CNS neuropil pattern (HPA tissue IHC). Review background in a negative control and the detection and blocking steps before interpreting a weak positive result (general IHC practice). |
| A cerebellar section has no convincing staining in GLUC cells. | This disagrees with the reported High GLUC cell signal (HPA tissue IHC). First confirm the expected cells are present and an IHC run control worked; an absent signal cannot alone distinguish a failed assay from section variation (general IHC practice). |
💡Expected SYT1 appearanceCall the result positive when cerebellar GLUC cell cytoplasm/membrane stains strongly or cerebral cortical neuropil stains at medium intensity (HPA tissue IHC); dominant nuclear signal or prominent adipocyte staining is discordant (HPA tissue IHC; UniProt P21579 subcellular location).
| Tissue and cell population | HPA reports selective CNS neuropil expression, High cerebellar GLUC cell cytoplasm/membrane staining, and Medium cortical neuropil staining; intestinal enterocytes are Low, so weak enterocyte color needs careful comparison with controls (HPA tissue IHC). |
| Protein topology | Residues 58–80 span a membrane; residues 1–57 face the vesicle and 81–422 face the cytoplasm (UniProt P21579 topology). This supports vesicle associated signal, but no antibody epitope is supplied, so topology cannot predict this antibody's retrieval response. |
| IHC evidence and antibody choice | HPA rates tissue staining Enhanced and lists HPA008394 and HPA064788 as IHC Enhanced (HPA tissue IHC; HPA antibodies). That supports the reported pattern; it does not prove that every staining condition or tissue will reproduce it. |
| Processing and isoforms | UniProt lists one 1–422 chain, no signal peptide or propeptide, and no isoforms in this record (UniProt P21579). No processing based explanation is supported here for a change in staining location or intensity. |
| IF/ICC: what can this guide infer? | HPA summarizes the subcellular location as Membrane, but supplies no ICC/IF image cell lines, and neither listed antibody has an ICC validation status (HPA subcellular; HPA antibodies). Treat an IF/ICC pattern as a separate question requiring its own validation. |
| Situation | Likely cause | Next action |
|---|---|---|
| No color in cerebellar GLUC cells. | The result conflicts with their reported High staining; the cause is undetermined from the tissue result alone (HPA tissue IHC). | Check section anatomy and run controls, then review retrieval, primary antibody use, and chromogenic detection as general IHC workflow checks; no SYT1 specific retrieval condition is established here (general IHC practice). |
| Diffuse color masks the neuropil. | Background can obscure the selective CNS neuropil pattern (HPA tissue IHC; general IHC practice). | Compare a no primary control, then review blocking, washing, and detection background before scoring; these are general IHC checks, not reported SYT1 specific fixes (general IHC practice). |
| Nuclei dominate the stain. | Nuclear localization is discordant with the reported vesicle membrane location and cytoplasm/membrane tissue pattern (UniProt P21579 subcellular location; HPA tissue IHC). | Check the negative control and counterstain, then reassess whether cytoplasm/membrane or neuropil has distinct signal before calling a positive (general IHC practice). |
| Adipocytes or adrenal glandular cells appear positive. | Those cell populations are reported Not detected; cross-reactivity or endogenous detection activity are possible explanations (HPA tissue IHC; general IHC practice). | Compare the same cell population in a negative control and inspect the detection system; do not extend the HPA cell specific finding to every cell in the whole tissue (general IHC practice). |
| Enterocytes show faint color. | HPA reports Low enterocyte staining in duodenum, small intestine, colon, rectum, and appendix (HPA tissue IHC). | Compare signal with matched background and record the scored cell population; faint enterocyte color alone neither confirms a strong positive nor proves an artefact (HPA tissue IHC; general IHC practice). |
| Can IF/ICC be judged from this IHC pattern? | The HPA subcellular summary says Membrane, but provides no ICC/IF image cell lines; ICC status is absent for both listed antibodies (HPA subcellular; HPA antibodies). | Use the IHC findings as context only and assess IF/ICC with its own controls and validation evidence; this section establishes no IF/ICC protocol conditions (general IHC/IF practice). |
Experiment evidence
IHC & IF images showing SYT1 staining
A02314-1 · IHCIHC analysis of Synaptotagmin 1 using anti-Synaptotagmin 1 antibody (A02314-1). Synaptotagmin 1 was detected in paraffin-embedded section of
A02314-1 · IHCIHC analysis of Synaptotagmin 1 using anti-Synaptotagmin 1 antibody (A02314-1). Synaptotagmin 1 was detected in paraffin-embedded section of
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000067715-SYT1/tissue/cerebral+cortex#imid_17620579
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000067715-SYT1/tissue/colon#imid_17643497
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000067715-SYT1/tissue/liver#imid_17643498
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000067715-SYT1/tissue/kidney#imid_17643507
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SYT1 IHC & IF
🧪Run cerebellum first and look for cytoplasmic or membrane staining in GLUC cells (HPA: cerebellum GLUC cells, High). Run adipose tissue as the negative tissue (HPA: adipocytes, Not detected); on the cerebellum slide, use cells outside the identified GLUC population as internal background comparators, without assuming they are SYT1-negative (HPA: cerebellum GLUC cells, High).
Positive control tissue: Cerebellum (GLUC cells - cytoplasm/membrane, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for SYT1; derive a cell-line control from the positive tissue's cell type (GLUC cells - cytoplasm/membrane) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only), species- and clonality-matched rabbit IgG isotype, and SYT1-knockout controls (caption: rabbit primary antibody; standard IHC control practice). For the biotin–SABC/DAB method, quench endogenous peroxidase and assess endogenous biotin staining (caption: biotinylated secondary antibody and SABC/DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A02314-1 paraffin-section caption does not state the fixative (caption: fixative unreported). The reported paraffin IHC example uses citrate retrieval at pH 6 for 20 minutes; the supplied evidence does not establish that frozen sections or IF are easier (caption: citrate retrieval; HPA: no ICC-IF cell-line images). In cerebellum, diffuse background can obscure the expected GLUC-cell cytoplasmic or membrane signal, so compare it with the no-primary slide (HPA: cerebellum GLUC cells, High; standard IHC practice).
HPA tissue IHC evidence for SYT1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | GLUC cells - cytoplasm/membrane | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SYT1 IHC Tips
Troubleshoot SYT1 staining in paraffin section chromogenic IHC using the catalog antibody’s tissue example, protein topology and tissue expression profile.
Which retrieval conditions should I try first for weak SYT1 staining?
Start with heat-mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A02314-1 tissue-IHC caption). The catalog antibody produced a chromogenic signal in a paraffin section after those conditions, followed by 10% goat serum blocking and 1 μg/mL primary antibody overnight at 4°C (datasheet A02314-1 tissue-IHC caption). If staining remains weak, compare retrieval duration on matched sections while keeping antibody concentration and detection constant (standard IHC practice). Include a known positive section in each comparison, and assess signal in the expected neuropil or cellular compartment rather than judging total brown area alone (HPA tissue IHC; UniProt P21579 localisation; standard IHC practice).
Could fixation explain a weak or uneven SYT1 result?
Target-specific SYT1 sensitivity to fixation is unknown from the supplied evidence; the catalog tissue example identifies a paraffin section but does not state its fixative (datasheet A02314-1 tissue-IHC caption). Record the fixative, fixation time and tissue processing history for every section before comparing staining intensity (standard IHC practice). When troubleshooting, process matched specimens consistently and vary only one preparation factor at a time, then apply the same citrate pH 6 retrieval and detection steps (datasheet A02314-1 tissue-IHC caption; standard IHC practice). A positive control processed alongside the test section helps distinguish a preparation problem from low local expression, but cannot establish a SYT1-specific fixation effect (standard IHC practice).
Where should convincing SYT1 staining appear in tissue?
Expect staining associated with synaptic vesicle-rich structures and cytoplasm, consistent with SYT1 localisation to secretory and synaptic vesicle membranes (UniProt P21579 localisation). In tissue IHC, the supplied profile describes selective CNS neuropil expression; cerebral cortex neuropil has medium staining, while cerebellar GLUC cells show high cytoplasm or membrane staining (HPA tissue IHC). Compare the observed distribution with those compartment and tissue references before changing the retrieval or antibody conditions (HPA tissue IHC; standard IHC practice). Diffuse nuclear staining alone lacks support from the supplied localisation record and warrants review of background, section quality and detection controls (UniProt P21579 localisation; standard IHC practice).
How does SYT1 topology affect epitope accessibility in paraffin sections?
SYT1 has a vesicular segment at residues 1–57, one transmembrane segment at 58–80, and a cytoplasmic segment at 81–422 (UniProt P21579 topology). Its two C2 domains span 142–261 and 273–406, while the supplied record lists no isoforms (UniProt P21579 domains and isoforms). The catalog caption does not identify the antibody epitope, so do not assign staining failure to a particular domain or modification without epitope information (datasheet A02314-1 tissue-IHC caption; standard IHC practice). If staining changes after retrieval, compare matched sections and check the expected tissue distribution before attributing that change to epitope exposure (HPA tissue IHC; standard IHC practice).
How should I investigate SYT1 by multiplex IF after chromogenic IHC?
Treat IF as a separate application: the supplied catalog example documents chromogenic staining in a paraffin section, with no IF validation stated (datasheet A02314-1 tissue-IHC caption). Pair SYT1 with an independently validated marker for the expected cell population, and assess colocalisation against the neuropil and cellular patterns reported for tissue IHC (HPA tissue IHC; standard IF practice). Choose fluorophores and detection channels after checking tissue autofluorescence and single-label controls, so background does not appear as colocalisation (standard IF practice). Because the catalog epitope is unspecified, establish whether it faces the vesicular or cytoplasmic side before choosing permeabilisation conditions, using SYT1 topology to guide that assessment (UniProt P21579 topology; standard IF practice).
What should I change if DAB background obscures SYT1 staining?
First compare the stained section with a no-primary control to assess secondary reagent, detection and tissue background (standard IHC practice). The catalog example used 10% goat serum blocking, a biotinylated secondary antibody, an avidin-biotin detection complex and DAB, so each step deserves review when diffuse color develops (datasheet A02314-1 tissue-IHC caption; standard IHC practice). Check peroxidase blocking and, for this detection design, assess endogenous biotin contribution with appropriate controls (standard IHC practice). Titrate primary antibody around the documented 1 μg/mL condition on matched sections, preserving the same retrieval and development time while comparing background with expected neuropil staining (datasheet A02314-1 tissue-IHC caption; HPA tissue IHC; standard IHC practice).
How should I quantify SYT1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and scoring rule before reviewing groups, then keep retrieval, imaging and DAB development consistent (standard IHC practice). In neuropil, quantify positive staining area or optical density per mm² of viable neuropil, excluding blank spaces and damaged edges (HPA tissue IHC; standard IHC practice). For a defined cell population, report the percentage of positive cells and intensity categories, or an H-score, with the counted cell population as denominator (standard IHC practice). Include a reference section in each staining run and report regions separately when comparing cerebellar GLUC cell staining with cerebral cortex neuropil, because the supplied patterns describe different compartments (HPA tissue IHC; standard IHC practice).
How can I distinguish a true SYT1 signal from artefact?
Favor a reproducible neuropil or cytoplasm and membrane pattern in the expected region over staining confined to tissue edges or damaged areas (HPA tissue IHC; UniProt P21579 localisation; standard IHC practice). Cerebral cortex neuropil and cerebellar GLUC cells provide supplied positive patterns, whereas caudate glial cells are reported as not detected (HPA tissue IHC). Review necrotic areas, no-primary controls and peroxidase blocking before calling isolated DAB deposits positive (standard IHC practice). If a glioma section stains under the catalog conditions, interpret its cellular source from section morphology and controls; the catalog caption establishes staining in that section but does not establish which cells produced it (datasheet A02314-1 tissue-IHC caption; standard IHC practice).
Boster reagents
Best SYT1 / Synaptotagmin-1 IHC Antibodies
A02314-1 has real paraffin-section IHC images from human glioma and melanoma and mouse and rat brain (catalog image captions); ICC is listed, with no IF image supplied (catalog applications and images).
Real IHC data
Anti-Synaptotagmin 1/SYT1 Antibody ®
Cat # A02314-1
A02314-1 has paraffin-section IHC images for human glioma and melanoma and mouse and rat brain (catalog image captions). Its listed applications include IHC and ICC, and its stated reactivity covers human, mouse and rat (catalog applications and reactivity).
Which to pick: Choose A02314-1 for paraffin-section IHC using its captioned citrate retrieval at pH 6 for 20 minutes and 1 μg/ml primary antibody (A02314-1 IHC image captions); the fixative is unreported (A02314-1 IHC image captions). For IF/ICC, A02314-1 lists ICC at 0.5–1 μg/ml, but no IF image is supplied (catalog applications, dilution and images). It is also the listed cross-species option for human, mouse and rat; clonality is unreported (catalog reactivity and clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P21579 (SYT1_HUMAN, Synaptotagmin-1).
- Human Protein Atlas. SYT1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. SYT1 subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. SYT1 antibody validation summary (2 antibodies).
- Retinal glycoprotein enrichment by concanavalin a enabled identification of novel membrane autoantigen synaptotagmin-1 in equine recurrent uveitis. PloS one 2012 — PMC3517615.
- Presynaptic Changes in Mouse Rod Photoreceptors During Early Retinitis Pigmentosa. Investigative ophthalmology & visual science 2025 — PMC12697692.
- Alterations of transcriptome signatures in head trauma-related neurodegenerative disorders. Scientific reports 2020 — PMC7264177.
- Ca(2+) sensor synaptotagmin-1 mediates exocytosis in mammalian photoreceptors. eLife 2019 — PMC6588344.
- PubMed PMID:1840599 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SYT1 (Synaptotagmin-1). Expected localisation CNS neuropil (HPA tissue IHC); vesicle membrane (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A02314-1). Validated IHC antibody: A02314-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (GLUC cells - cytoplasm/membrane); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human glioma tissue; fixative not specified (datasheet A02314-1); 2. Fixation: Image fixative and duration unreported (datasheet A02314-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A02314-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02314-1); 8. Primary antibody: Rabbit anti-SYT1, 0.5-1μg/ml (datasheet A02314-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02314-1). Watch for: Fixation: Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific); Caveat: Melanocyte expression may add non-neural signal (UniProt); Isoform / epitope: 0 isoforms; vesicular versus cytoplasmic epitope matters (UniProt); Regulation: Expression regulation not reported (UniProt). Evidence: UniProt P21579, HPA tissue IHC · Enhanced, HPA ICC-IF · Membrane, Datasheet A02314-1, PMC7264177. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SYT1/immunohistochemistry-ihc-guide.